Clinical trials offer treatment options that are not otherwise available to cancer patients. Investigational cancer drugs and drug combinations may represent the best hope for certain patients, but they can only be given in the context of a clinical study.
Although many patients could personally benefit from cancer trials, many do not enroll. According to a 2010 National Institute of Health workshop on U.S. clinical research, only 3% of adult cancer patients enter trials. In a recent review of over 500 National Cancer Institute trials, almost 40% were unable to enroll a sufficient number of patients. This lack of participation is more than just a problem for medical research. It is a problem for individual patients. For some patients, the new therapy may be their best chance. Lack of awareness and common misconceptions, however, are often a barrier.
One of the most misunderstood aspects of trials is the use of placebos. Cancer patients shy away because they are afraid of receiving a placebo instead of therapy. It cannot be overemphasized; this will not happen in a